Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06773208 Clinical Landscape Report 2026
16 October 2026
NCT06773208 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Arsenic Trioxide in Myeloid Tumor: NCT06778187 Clinical Landscape Report 2026
16 October 2026
NCT06778187 clinical landscape for Myeloid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RD-0605 in Idiopathic Inflammatory Myopathies: NCT06775912 Clinical Landscape Report 2026
16 October 2026
NCT06775912 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
CLSP-1025 in Pancreatic adenocarcinoma: NCT06778863 Clinical Landscape Report 2026
16 October 2026
NCT06778863 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Soficitinib in Dermatitis, Atopic: NCT06775860 Clinical Landscape Report 2026
16 October 2026
NCT06775860 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Non-Muscle Invasive Bladder Neoplasms: NCT06781879 Clinical Landscape Report 2026
16 October 2026
NCT06781879 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Venetoclax in Relapsing acute myeloid leukemia: NCT06783790 Clinical Landscape Report 2026
16 October 2026
NCT06783790 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
NK cell(HCPA) in Acute Myeloid Leukemia: NCT06783478 Clinical Landscape Report 2026
16 October 2026
NCT06783478 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Bladder Cancer: CTRI/2025/01/079010 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/01/079010 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in IDH1 Mutation Acute Myeloid Leukemia: NCT06782542 Clinical Landscape Report 2026
16 October 2026
NCT06782542 clinical landscape for IDH1 Mutation Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Rifaximin in Enteritis: NCT06783153 Clinical Landscape Report 2026
16 October 2026
NCT06783153 clinical landscape for Enteritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iberdomide Hydrochloride in Recurrent Multiple Myeloma: NCT06785415 Clinical Landscape Report 2026
16 October 2026
NCT06785415 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.